OMNIX MEDICAL TO PRESENT AT BIOTECH SHOWCASE™ 2020 IN SAN FRANCISCO

January 3, 2020

Offering new hope for patients suffering from drug resistant infections

SAN FRANCISCO, Calif., January 3, 2020 – Omnix Medical has scheduled a company presentation at Biotech Showcase™ 2020 to be held on January 13, 2020, during the most important week in healthcare at the Hilton San Francisco Union Square.

Niv Bachnoff, CSO, will be presenting Omnix Medical at Biotech Showcase as follows:

Date: Monday, January 13, 2020
Time: 3:30 PM (PST)
Room: Franciscan D (Ballroom Level)
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)

ABOUT OMNIX MEDICAL

Omnix Medical is a biotechnology company focused on discovering and developing peptide therapeutic for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Hospital-acquired infections are currently the fourth leading cause of death in the United States, following heart disease, cancer and stroke.

Omnix Medical’s molecules (OMN6, OMN7 and OMN11) are developed for the treatment of these infections via systemic IV administration. Our lead product OMN6 targets A. baumannii. Clinical trials will begin in 2020.

Omnix’s technology is inspired by the innate immune system of insects, employing a strategy that has been proven very efficient for 250 million years. Insects combat pathogenic bacteria using a unique family of Antimicrobial Peptides that physically damage bacterial membranes with no toxic effects. The rapid bactericidal Mechanism of Action employed by these peptides is active against Gram(-) multidrug-resistant pathogens, the ESKAPE bacteria: K. pneumonia spp, A. baumannii, P. aeruginosa and Enterobacter spp. These bacteria are the most serious and urgent threats to public health leading to ~50% mortality among infected patients in Intensive Care Units.

Omnix Medical was founded in 2015. Headquartered in Jerusalem, Israel, the Company employs eight scientists advancing in-house research and development as well as closely directing studies with top-tier international contract research organizations.

“We are delighted that Omnix Medical will be presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”

ABOUT BIOTECH SHOWCASE

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks.

Investor Contact

Moshik Cohen-Kutner, CEO
+972-50-8698218

Rom Lakritz, CFO/COO
+1 646 9346699
contact@omnixmedical.com

Media Contact

Niv Bachnoff, CSO
+ 972-54-238-6023
niv@omnixmedical.com

Related Links

Twitter twitter.com/MedicalOmnix

LinkedIn linkedin.com/company/omnix-medical

More To Explore

Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6

Designation underlines the need for novel, first-in-class antimicrobials for the treatment of infections with Gram-negative bacteria Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for

Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6

JERUSALEM, Israel, November 20, 2023 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced that the U.S.

OMN6 – Omnix Medical’s Lead Antimicrobial Peptide Receives Notice of Allowance from the Indian Patent Office

We are here to announce that the Indian Patent Office has issued a Notice of Allowance for Omnix Medical’s lead antimicrobial peptide for the treatment

Contact Us

Reach US

A-2-Z - Digital Accessibility and Marketing

Omnix Medical Ltd. is committed to making its website and all its electronic information easier to use and more accessible for people with disabilities. The company’s website was created and/or updated according to the provisions of the Equal Rights for People with Disabilities Law, 5748-1998, and the delegated legislation stemming from it, and it fully complies with the W3C Web Content Accessibility Guidelines 2.0, AA level.

Omnix Medical Ltd. will continue its efforts to constantly improve the accessibility of its website and information in the belief that it is our collective moral obligation to allow seamless, accessible, and unhindered use also for those of us with disabilities.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 966627 (OMNIX MEDICAL).